» Articles » PMID: 30460631

Characterization of IPSCs Derived from Low Grade Gliomas Revealed Early Regional Chromosomal Amplifications During Gliomagenesis

Overview
Journal J Neurooncol
Publisher Springer
Date 2018 Nov 22
PMID 30460631
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: IDH1 mutation has been identified as an early genetic event driving low grade gliomas (LGGs) and it has been proven to exerts a powerful epigenetic effect. Cells containing IDH1 mutation are refractory to epigenetical reprogramming to iPSC induced by expression of Yamanaka transcription factors, a feature that we employed to study early genetic amplifications or deletions in gliomagenesis.

Methods: We made iPSC clones from freshly surgically resected IDH1 mutant LGGs by forced expression of Yamanaka transcription factors. We sequenced the IDH locus and analyzed the genetic composition of multiple iPSC clones by array-based comparative genomic hybridization (aCGH).

Results: We hypothesize that the primary cell pool isolated from LGG tumor contains a heterogeneous population consisting tumor cells at various stages of tumor progression including cells with early genetic lesions if any prior to acquisition of IDH1 mutation. Because cells containing IDH1 mutation are refractory to reprogramming, we predict that iPSC clones should originate only from LGG cells without IDH1 mutation, i.e. cells prior to acquisition of IDH1 mutation. As expected, we found that none of the iPSC clones contains IDH1 mutation. Further analysis by aCGH of the iPSC clones reveals that they contain regional chromosomal amplifications which are also present in the primary LGG cells.

Conclusions: These results indicate that there exists a subpopulation of cells harboring gene amplification but without IDH1 mutation in the LGG primary cell pool. Further analysis of TCGA LGG database demonstrates that these regional chromosomal amplifications are also present in some cases of low grade gliomas indicating they are reoccurring lesions in glioma albeit at a low frequency. Taken together, these data suggest that regional chromosomal alterations may exist prior to the acquisition of IDH mutations in at least some cases of LGGs.

Citing Articles

Prime editing-mediated correction of the CFTR W1282X mutation in iPSCs and derived airway epithelial cells.

Li C, Liu Z, Anderson J, Liu Z, Tang L, Li Y PLoS One. 2023; 18(11):e0295009.

PMID: 38019847 PMC: 10686454. DOI: 10.1371/journal.pone.0295009.


Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy.

Chehelgerdi M, Dehkordi F, Chehelgerdi M, Kabiri H, Salehian-Dehkordi H, Abdolvand M Mol Cancer. 2023; 22(1):189.

PMID: 38017433 PMC: 10683363. DOI: 10.1186/s12943-023-01873-0.


Application of Induced Pluripotent Stem Cells in Malignant Solid Tumors.

He R, Weng Z, Liu Y, Li B, Wang W, Meng W Stem Cell Rev Rep. 2023; 19(8):2557-2575.

PMID: 37755647 PMC: 10661832. DOI: 10.1007/s12015-023-10633-y.


Preclinical Models of Low-Grade Gliomas.

Dasgupta P, Balasubramanyian V, de Groot J, Majd N Cancers (Basel). 2023; 15(3).

PMID: 36765553 PMC: 9913857. DOI: 10.3390/cancers15030596.


Generation of chromosome 1p/19q co-deletion by CRISPR/Cas9-guided genomic editing.

Li C, Liu Z, Zhang X, Wang H, Friedman G, Ding Q Neurooncol Adv. 2022; 4(1):vdac131.

PMID: 36225650 PMC: 9547542. DOI: 10.1093/noajnl/vdac131.


References
1.
Ostrom Q, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J . CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol. 2014; 16 Suppl 4:iv1-63. PMC: 4193675. DOI: 10.1093/neuonc/nou223. View

2.
Yan H, Parsons D, Jin G, McLendon R, Rasheed B, Yuan W . IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009; 360(8):765-73. PMC: 2820383. DOI: 10.1056/NEJMoa0808710. View

3.
Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A . Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol. 2009; 118(4):469-74. DOI: 10.1007/s00401-009-0561-9. View

4.
Dang L, White D, Gross S, Bennett B, Bittinger M, Driggers E . Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009; 462(7274):739-44. PMC: 2818760. DOI: 10.1038/nature08617. View

5.
Pietrak B, Zhao H, Qi H, Quinn C, Gao E, Boyer J . A tale of two subunits: how the neomorphic R132H IDH1 mutation enhances production of αHG. Biochemistry. 2011; 50(21):4804-12. DOI: 10.1021/bi200499m. View